<?xml version="1.0" encoding="UTF-8"?>
<p id="Par2">Peripheral T cell lymphomas (PTCLs) are an aggressive group of non-Hodgkin lymphomas (NHLs), accounting for 5–10% of all NHLs in Western countries and approximately 20% of NHLs in Japan [
 <xref ref-type="bibr" rid="CR1">1</xref>, 
 <xref ref-type="bibr" rid="CR2">2</xref>]. The most common PTCL subtypes are PTCL, not otherwise specified (PTCL-NOS); anaplastic large cell lymphoma (ALCL); and angioimmunoblastic T cell lymphoma (AITL) [
 <xref ref-type="bibr" rid="CR3">3</xref>, 
 <xref ref-type="bibr" rid="CR4">4</xref>]. Newly diagnosed PTCL is most frequently treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP-like chemotherapies [
 <xref ref-type="bibr" rid="CR5">5</xref>–
 <xref ref-type="bibr" rid="CR8">8</xref>]. Although most patients respond initially, outcomes remain poor except in patients with anaplastic lymphoma kinase (ALK)-positive ALCL [
 <xref ref-type="bibr" rid="CR5">5</xref>]. Median survival in a cohort of 153 North American patients with first-relapsed/refractory PTCLs was 5.5 months, underscoring the need for new treatments in this setting [
 <xref ref-type="bibr" rid="CR9">9</xref>].
</p>
